Clinical Trial Update: Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) evaluating on-demand treatment of bleeding in Hemophilia A or B wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia with Inhibitors

Drugs mentioned

• rVIIa-FP (CSL689) (recombinant Factor VIIa fusion protein)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors | Phase 2, Phase 3 | Status: TERMINATED